Rapid response of recalcitrant linear IgA bullous dermatosis to omalizumab: A case report and literature review

Dermatologic TherapyVolume 35, Issue 12 e15920 LETTER Rapid response of recalcitrant linear IgA bullous dermatosis to omalizumab: A case report and literature review Xin Tong, Xin Tong Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, ChinaSearch for more papers by this authorLong Geng, Long Geng Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, ChinaSearch for more papers by this authorXing-Hua Gao, Xing-Hua Gao orcid.org/0000-0001-8809-8564 Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, ChinaSearch for more papers by this authorHong-Hui Xu, Corresponding Author Hong-Hui Xu [email protected] Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, China Correspondence Hong-Hui Xu, Department of Dermatology, The First Hospital of China Medical University, Shenyang, China. Email: [email protected]Search for more papers by this author Xin Tong, Xin Tong Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, ChinaSearch for more papers by this authorLong Geng, Long Geng Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, ChinaSearch for more papers by this authorXing-Hua Gao, Xing-Hua Gao orcid.org/0000-0001-8809-8564 Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, ChinaSearch for more papers by this authorHong-Hui Xu, Corresponding Author Hong-Hui Xu [email protected] Department of Dermatology, The First Hospital of China Medical University, Shenyang, China National Health Commission Key Laboratory of Immunodermatology, Shenyang, China Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, China Correspondence Hong-Hui Xu, Department of Dermatology, The First Hospital of China Medical University, Shenyang, China. Email: [email protected]Search for more papers by this author First published: 11 October 2022 https://doi.org/10.1111/dth.15920Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Maalouf NS, Hanna D. Linear IgA bullous dermatosis successfully treated with omalizumab: a case report. JAAD Case Rep. 2019; 5(11): 966-969. 10.1016/j.jdcr.2019.08.019 PubMedGoogle Scholar 2Patel NH, Padhiyar JK, Patel TD, Trivedi NS, Chandibhamar VS, Raval R. A case of linear IgA bullous dermatosis successfully treated with omalizumab. Indian J Dermatol. 2020; 65(6): 543-545. 10.4103/ijd.IJD_55_20 PubMedWeb of Science®Google Scholar 3García-Gil MF, Franco Rubio JI, Álvarez-Salafranca M, Monte Serrano J, Prieto-Torres L. Flame figures in linear immunoglobulin a bullous dermatosis secondary to parvovirus B19 infection. Am J Dermatopathol. 2021; 43(1): 60-62. 10.1097/DAD.0000000000001690 PubMedWeb of Science®Google Scholar 4Haulrig MB, Nielsen SL, Elberling J, Skov L. Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: a case report. Clin Case Rep. 2022; 10(3):e05368. 10.1002/ccr3.5368 PubMedWeb of Science®Google Scholar 5Chanal J, Ingen-Housz-Oro S, Ortonne N, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013; 169(5): 1041-1048. 10.1111/bjd.12488 CASPubMedWeb of Science®Google Scholar 6Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006; 117(6): 1493-1499. 10.1016/j.jaci.2006.02.028 CASPubMedWeb of Science®Google Scholar Volume35, Issue12December 2022e15920 ReferencesRelatedInformation